Pemivibart

Pemivibart, sold under the brand name Pemgarda, is a monoclonal antibody medication authorized for the pre-exposure prophylaxis (prevention) of COVID19.

The US Food and Drug Administration (FDA) issued an emergency use authorization for pemivibart in March 2024.

Medical uses
In the US, pemivibart is authorized for the pre-exposure prophylaxis (prevention) of COVID19 in certain adults and adolescents (12 years of age and older weighing at least 40 kg. It is authorized for individuals who are not currently infected with SARSCoV2 and who have not had a known recent exposure to an individual infected with SARSCoV2; and who have moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID19 vaccination.

Names
Pemivibart is the international nonproprietary name.